IMPALA – 2

The aim of this trial is to confirm if Molgramostim Nebulizer Solution (inhaled molgramostim) improves function of the lungs in patients with autoimmune pulmonary alveolar proteinosis (aPAP).

Key Eligibility Criteria

Adult subjects with a clinical diagnosis of autoimmune pulmonary alveolar proteinosis (a PAP)

Therapeutic Area

Respiratory Medicine

Type of Study

Phase 3 - Clinical Trial

Study Status

Open Recruiting

Sponsor

SAVARA

Principal Investigator

Dr. Cormac McCarthy

Contact

laura.feeney@ucd.ie